Brexit blocks English children's access to brain tumor drug

The regulatory and bureaucratic barriers that emerged following the United Kingdom's withdrawal from the European Union (Brexit) have severely restricted patients in the country's access to some vital drugs. Experts state that English children diagnosed with aggressively progressing brain cancer are being deprived of new-generation treatments that could extend their lives. The new trade and drug licensing rules brought by the Brexit process have led to delays in the initiation of clinical trials and increased costs. This situation has reached a dimension that negatively affects not only a specific patient group but also the English healthcare system and pharmaceutical supply chains in general. Experts emphasize that delays in life-saving treatments due to political decisions are unacceptable.

At the center of the issue is the treatment process of children diagnosed with an aggressive type of brain cancer. The disease in question is known as a serious health problem that is seen especially in children and is extremely difficult to treat. Experimental drugs developed for these patients, which are thought to significantly extend their lives, can pass the approval process more quickly in European Union member countries. However, in the post-Brexit period, the UK is forced to carry out these processes independently and more slowly because it remains outside the EU's joint drug licensing networks. Therefore, the entry of these new treatments that can be used in newborns and children into the country is delayed for days or months.

Experts and health officials are calling for urgent action, drawing attention to the destructive effects of Brexit on the English pharmaceutical market. Delays in initiating clinical trials and increased drug entry costs cause pharmaceutical companies to prioritize the UK market secondarily. Most international pharmaceutical companies prefer to conduct their trials and launches primarily in the EU domestic market because this region represents a larger population and a joint approval mechanism. It is stated that this situation also lowers the quality of medical research in the UK and weakens the country's competitive power in the global scientific world. Many professionals working in the fields of pharmaceutical endocrinology and oncology state that this picture is unsustainable.

To resolve this crisis, health authorities and academics are calling on the UK government to reconsider its relations with Europe. It is argued that the government should make new and closer cooperation agreements with the European Union to guarantee the supply of life-saving treatments. Experts state that the complete severing of the UK's ties with the European Medicines Agency (EMA) has had severe consequences. Re-establishing regulatory alignment between the two parties could ensure both faster initiation of clinical trials and more reasonable drug pricing. If this step is taken, it is thought that new doors could be opened for the cure of many untreatable diseases.

As a result, while the political and economic consequences of Brexit are debated, it becomes clear that such direct and bitter effects in the field of healthcare cannot be ignored. The transformation of the UK's independent drug policies into a structure that will punish the most vulnerable groups, such as child cancer patients, is a major source of concern. Amid the government's promises to reset relations with Europe, ensuring uninterrupted access to medical treatments is seen as one of the top priorities. This process once again highlights how critical health and drug supply chain independence is in future trade agreements. All these developments clearly reveal the concrete and sometimes irreversible impacts of political decisions on human lives.